The BRCA1 and BRCA2 gene patents, owned by Myriad Genetics, have been struck down by a judge in Federal court. The suit, brought by the ACLU and several other partners, argued that genes are “natural” and thus cannot be patented. Patenting, the argued, lead to a stifling of innovation. BRCA1 and BRCA2 gene mutations have been associated with breast and ovarian cancer.
{ 2010 04 02 }
Post a Comment